Share Repurchase and Equity Incentive - The company repurchased 514,900 shares, accounting for 0.9159% of the total share capital, for the purpose of an equity incentive plan[7]. - The 2024 equity incentive plan was approved, granting 514,900 restricted stocks at a price of 9.10 RMB per share to 37 individuals[9]. - The total amount paid for the share repurchase reached 6,001,548.78 CNY, accounting for 60.02% of the planned repurchase budget[132]. - The share repurchase plan aims to buy back between 375,000 and 625,000 shares, representing 0.67% to 1.11% of the total share capital[130]. - The company completed the 2024 equity incentive plan, granting 514,900 restricted shares at a price of 9.10 CNY per share[129]. Financial Performance - The company's operating revenue for 2024 reached ¥270,466,229.84, representing a year-over-year increase of 19.54% compared to ¥226,253,170.32 in 2023[28]. - The net profit attributable to shareholders for 2024 was ¥49,664,051.16, a 2.25% increase from ¥48,572,460.01 in 2023[28]. - The net profit after deducting non-recurring gains and losses increased by 35.18% to ¥45,245,491.34 in 2024 from ¥33,470,776.11 in 2023[28]. - Total assets at the end of 2024 amounted to ¥561,586,391.04, reflecting a growth of 5.29% from ¥533,395,393.75 in 2023[29]. - The company's total liabilities slightly decreased by 0.22% to ¥66,072,077.85 in 2024 from ¥66,215,014.88 in 2023[29]. - The weighted average return on equity based on net profit attributable to shareholders was 10.54% in 2024, down from 11.62% in 2023[28]. - The basic earnings per share for 2024 was ¥0.89, a decrease of 2.20% compared to ¥0.91 in 2023[28]. - The operating cash flow for 2024 was ¥41,462,010.43, showing a slight increase of 0.04% from ¥41,446,334.08 in 2023[29]. - The company's inventory turnover ratio improved to 1.89 in 2024 from 1.82 in 2023[30]. - The company's main business income increased by 20.20% to ¥269,420,880.33, compared to ¥224,150,865.51 in the previous year[68]. Research and Development - The company obtained several invention patents, including a low-impurity content synthesis method for vortioxetine and a preparation method for 4-amino-2,6-dichloropyridine[8]. - The company is recognized as a national high-tech enterprise, holding 13 invention patents and 19 utility model patents, indicating strong R&D capabilities[40]. - The company's R&D expenses grew by 29.69% to ¥20,513,979.77, reflecting increased investment in personnel and materials[67]. - The company has completed several R&D projects, including the optimization of production processes for various pharmaceutical intermediates, which are expected to enhance product quality and reduce costs[98][99]. - The company emphasizes technology innovation by increasing investment in R&D resources and closely monitoring industry trends to enhance product performance and functionality[117]. Market and Business Strategy - The company focuses on the research and sales of advanced pharmaceutical intermediates and raw materials[22]. - The company operates in the pharmaceutical manufacturing industry, specifically in the production of chemical drug raw materials[22]. - The company maintains a stable long-term cooperation with downstream clients, including well-known pharmaceutical companies in South Korea and Japan[40]. - The company’s business model remains unchanged, focusing on the R&D, production, and sales of high-end pharmaceutical intermediates and APIs[48]. - The company plans to expand its market presence through strategic investments and new product development initiatives[92]. Compliance and Governance - The company has a commitment to maintaining the accuracy and completeness of its financial reporting, as confirmed by its management[13]. - The company has no significant litigation or arbitration matters during the reporting period[127]. - There are no instances of shareholders or related parties occupying or transferring company funds or assets[127]. - The company has committed to avoid competition with its controlling shareholders and related parties[134]. - The company will ensure that all related transactions are conducted in accordance with market principles to protect the interests of all shareholders[156]. Shareholder and Management Information - The company has a total of 9 board members and 3 supervisors, with 4 senior management personnel[184]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 2.9944 million[193]. - The company has a total of 29,131,485 shares held by directors, accounting for 51.82% of total shares[186]. - The company’s independent directors have not changed during the reporting period[189]. - The company’s major shareholders agreed that any profits from violations of commitments would be returned to the company, and they would not transfer their shares until the violations are rectified[162]. Employee and Workforce Development - The total number of employees increased from 424 to 439, with a net addition of 19 employees during the reporting period[197]. - The number of technical personnel rose from 76 to 91, reflecting a growth of 19.74%[197]. - The company has implemented a comprehensive employee training program to enhance professional skills and management levels[199]. - The company maintains a full labor contract system for all employees, ensuring compliance with social insurance and tax regulations[199]. - The number of employees with a doctoral degree increased from 2 to 4, representing a 100% increase[198].
峆一药业(430478) - 2024 Q4 - 年度财报